These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 21694902)

  • 1. New strategies for the treatment of hepatitis C virus infection and implications of resistance to new direct-acting antiviral agents.
    Quer J; Buti M; Cubero M; Guardia J; Esteban R; Esteban JI
    Infect Drug Resist; 2010; 3():133-45. PubMed ID: 21694902
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New direct-acting antivirals' combination for the treatment of chronic hepatitis C.
    Asselah T; Marcellin P
    Liver Int; 2011 Jan; 31 Suppl 1():68-77. PubMed ID: 21205141
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hepatocellular Carcinoma Mechanisms Associated with Chronic HCV Infection and the Impact of Direct-Acting Antiviral Treatment.
    Dash S; Aydin Y; Widmer KE; Nayak L
    J Hepatocell Carcinoma; 2020; 7():45-76. PubMed ID: 32346535
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A pharmacological profile of ribavirin and monitoring of its plasma concentration in chronic hepatitis C infection.
    Naik GS; Tyagi MG
    J Clin Exp Hepatol; 2012 Mar; 2(1):42-54. PubMed ID: 25755405
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Therapy of chronic hepatitis C virus infection in the era of direct-acting and host-targeting antiviral agents.
    Conteduca V; Sansonno D; Russi S; Pavone F; Dammacco F
    J Infect; 2014 Jan; 68(1):1-20. PubMed ID: 24012819
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Autoantibodies to cytoplasmic rods and rings in patients with hepatitis C virus infection treated with direct-acting antivirals: The role of prior treatment with interferon plus ribavirin.
    Alsius M; Ferri MJ; Buxó M; López C; Serra I; Queralt X; Acero D
    Gastroenterol Hepatol; 2019 Feb; 42(2):82-89. PubMed ID: 30446175
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hepatitis C Viral Kinetics in the Era of Direct Acting Antiviral Agents and IL28B.
    Dahari H; Guedj J; Perelson AS; Layden TJ
    Curr Hepat Rep; 2011 Jul; 10(3):214-227. PubMed ID: 22180724
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Deep sequencing and phylogenetic analysis of variants resistant to interferon-based protease inhibitor therapy in chronic hepatitis induced by genotype 1b hepatitis C virus.
    Sato M; Maekawa S; Komatsu N; Tatsumi A; Miura M; Muraoka M; Suzuki Y; Amemiya F; Takano S; Fukasawa M; Nakayama Y; Yamaguchi T; Uetake T; Inoue T; Sato T; Sakamoto M; Yamashita A; Moriishi K; Enomoto N
    J Virol; 2015 Jun; 89(11):6105-16. PubMed ID: 25810555
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase III results of Boceprevir in treatment naïve patients with chronic hepatitis C genotype 1.
    Manns MP; Markova AA; Calle Serrano B; Cornberg M
    Liver Int; 2012 Feb; 32 Suppl 1():27-31. PubMed ID: 22212568
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antiviral Therapy in Patients with Hepatitis C Virus-Induced Cirrhosis.
    Bailly F; Pradat P; Virlogeux V; Zoulim F
    Dig Dis; 2015; 33(4):613-23. PubMed ID: 26159282
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of hepatitis B and C in children.
    El-Shabrawi M; Hassanin F
    Minerva Pediatr; 2014 Oct; 66(5):473-89. PubMed ID: 25253190
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hepatitis C Virus: Viral Quasispecies and Genotypes.
    Tsukiyama-Kohara K; Kohara M
    Int J Mol Sci; 2017 Dec; 19(1):. PubMed ID: 29271914
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Resistance to direct antiviral agents in patients with hepatitis C virus infection.
    Sarrazin C; Zeuzem S
    Gastroenterology; 2010 Feb; 138(2):447-62. PubMed ID: 20006612
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of novel small molecule inhibitors against the NS3/4A protease of hepatitis C virus genotype 4a.
    El-Sayed SM; Ali MAM; El-Gendy BEM; Dandash SS; Issac Y; Saad R; Azab MM; Mohamed MR
    Curr Pharm Des; 2018; 24(37):4484-4491. PubMed ID: 30501598
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antiviral therapy for hepatitis C virus: beyond the standard of care.
    Delang L; Coelmont L; Neyts J
    Viruses; 2010 Apr; 2(4):826-866. PubMed ID: 21994657
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hepatitis C virus: standard-of-care treatment.
    Pawlotsky JM
    Adv Pharmacol; 2013; 67():169-215. PubMed ID: 23886001
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Side-effects of pegylated interferon plus ribavirin therapy with or without protease inhibitor direct acting antiviral agents during treatment of chronic hepatitis C virus infection].
    Hunyady B; Kovács B; Battyáni Z
    Orv Hetil; 2011 Dec; 152(50):1997-2009. PubMed ID: 22112373
    [TBL] [Abstract][Full Text] [Related]  

  • 18. All Oral Interferon-free Direct-acting Antivirals as Combination Therapies to Cure Hepatitis C.
    Shahid I; Ibrahim MM
    Curr Mol Med; 2018; 18(7):409-435. PubMed ID: 30608042
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Direct-acting antivirals in hepatitis C virus (HCV)-infected and HCV/HIV-coinfected patients: real-life safety and efficacy.
    Milazzo L; Lai A; Calvi E; Ronzi P; Micheli V; Binda F; Ridolfo AL; Gervasoni C; Galli M; Antinori S; Sollima S
    HIV Med; 2017 Apr; 18(4):284-291. PubMed ID: 27477612
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The hepatitis C revolution part 1: antiviral treatment options.
    Thiagarajan P; Ryder SD
    Curr Opin Infect Dis; 2015 Dec; 28(6):563-71. PubMed ID: 26524328
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.